What Trevi Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 4 | 4 |
| Total trades | 6 | 7 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 39,473 | 43,698 |
| Disposed | 39,473 | 39,473 |
| Net activity | +0 | +4,225 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Heffernan Michael Thomas | Director | Sep 15 | Disclosed 10b5-1 sale · S | −100 | $15.88 | −$1.59K | 6,351 |
| Heffernan Michael Thomas | Director | Sep 15 | Disclosed 10b5-1 sale · S | −20,952 | $15.09 | −$316K | 6,451 |
| Heffernan Michael Thomas | Director | Sep 15 | Exercise / conversion · M | +21,052 | $3.33 | +$70.1K | 27,403 |
| Heffernan Michael Thomas | Director | Sep 15 | Disclosed 10b5-1 sale · S | −100 | $15.88 | −$1.59K | 6,351 |
| Heffernan Michael Thomas | Director | Sep 15 | Disclosed 10b5-1 sale · S | −18,321 | $15.09 | −$276K | 6,451 |
| Heffernan Michael Thomas | Director | Sep 15 | Exercise / conversion · M | +18,421 | $3.04 | +$56K | 24,772 |
| Galletta Christopher | See Remarks | Dec 02 | Exercise / conversion · M | +4,225 | $0.51 | +$2.16K | 26,095 |
| Walker Paul Edward | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Baskett Forest | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| New Enterprise Associates 16, L.p. | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Chang Carmen | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Makhzoumi Mohamad | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Florence Anthony A. Jr. | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Sandell Scott D | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Behbahani Ali | 10% owner | Apr 17 | In/At-money Exercise · X | +1,851,852 | $1.37 | +$2.54M | 12,273,280 |
| Sciascia Thomas | Chief Scientific Officer | Mar 25 | Open-market sale · S | −2,631 | $6.60 | −$17.4K | 221,373 |
| Sciascia Thomas | Chief Scientific Officer | Mar 25 | Exercise / conversion · M | +2,631 | $1.43 | +$3.76K | 224,004 |
| Good Jennifer L | President & CEO | Mar 21 | Open-market sale · S | −5,263 | $6.58 | −$34.6K | 213,313 |
| Good Jennifer L | President & CEO | Mar 21 | Exercise / conversion · M | +5,263 | $1.43 | +$7.53K | 218,576 |
| Simon Farrell | Chief Commercial Officer | Mar 10 | Open-market sale · S | −4,350 | $7.15 | −$31.1K | 76,900 |
Loading...
